NCT06431113View on ClinicalTrials.gov

Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 27, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions
GlaucomaNeuroprotection
Interventions
COMBINATION_PRODUCT

Citicoline 500 mg plus Homotaurine 50 mg plus Pyrroloquinoline quinone (Neuprozin Mito® )

treatment for 4 months and then cross over to the other therapy

Trial Locations (2)

27100

Gemma Caterina Maria Rossi, Pavia

80100

Clinica Oculistica Università Federico II, Napoli

All Listed Sponsors
collaborator

Federico II University

OTHER

collaborator

University of Roma La Sapienza

OTHER

lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT06431113 - Effect of Fixed Combination Citicoline Homotaurine and Pyrroloquinoline Quinone on Pattern-electroretinogram in Glaucoma | Biotech Hunter | Biotech Hunter